2. Flores BC, Klinger DR, Rickert KL, Barnett SL, Welch BG, White JA, et al. Management of intracranial aneurysms associated with arteriovenous malformations. Neurosurg Focus 2014;37:E11
3. Rangel-Castilla L, Russin JJ, Martinez-Del-Campo E, Soriano-Baron H, Spetzler RF, Nakaji P. Molecular and cellular biology of cerebral arteriovenous malformations: a review of current concepts and future trends in treatment. Neurosurg Focus 2014;37:E1
4. Abecassis IJ, Xu DS, Batjer HH, Bendok BR. Natural history of brain arteriovenous malformations: a systematic review. Neurosurg Focus 2014;37:E7
6. Gross BA, Du R. Natural history of cerebral arteriovenous malformations: a meta-analysis. J Neurosurg 2013;118:437-443.
7. Fukuda K, Majumdar M, Masoud H, Nguyen T, Honarmand A, Shaibani A, et al. Multicenter assessment of morbidity associated with cerebral arteriovenous malformation hemorrhages. J Neurointerv Surg 2017;9:664-668.
8. Mohr JP, Parides MK, Stapf C, Moquete E, Moy CS, Overbey JR, et al, International ARUBA Investigators. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. Lancet 2014;383:614-621.
9. Bambakidis NC, Cockroft KM, Hirsch JA, Connolly ES, Amin-Hanjani S, Meyers PM, et al. The case against a randomized trial of unruptured brain arteriovenous malformations: misinterpretation of a flawed study. Stroke 2014;45:2808-2810.
10. Knopman J, Stieg PE. Management of unruptured brain arteriovenous malformations. Lancet 2014;383:581-583.
11. Rutledge WC, Abla AA, Nelson J, Halbach VV, Kim H, Lawton MT. Treatment and outcomes of ARUBA-eligible patients with unruptured brain arteriovenous malformations at a single institution. Neurosurg Focus 2014;37:E8
12. Gross BA, Scott RM, Smith ER. Management of brain arteriovenous malformations. Lancet 2014;383:1635
13. Link TW, Winston G, Schwarz JT, Lin N, Patsalides A, Gobin P, et al. Treatment of unruptured brain arteriovenous malformations: a single-center experience of 86 patients and a critique of the a randomized trial of unruptured brain arteriovenous malformations (ARUBA) trial. World Neurosurg 2018;120:e1156-e1162.
14. Ding D, Starke RM, Kano H, Mathieu D, Huang P, Kondziolka D, et al. Radiosurgery for cerebral arteriovenous malformations in a randomized trial of unruptured brain arteriovenous malformations (ARUBA)-eligible patients: a multicenter study. Stroke 2016;47:342-349.
15. Pollock BE, Link MJ, Brown RD. The risk of stroke or clinical impairment after stereotactic radiosurgery for ARUBA-eligible patients. Stroke 2013;44:437-441.
16. Tsuji A, Nozaki K. A prospective and retrospective study of cerebral AVM treatment strategies 1990-2014. Acta Neurochir Suppl 2016;123:135-139.
17. Javadpour M, Al-Mahfoudh R, Mitchell PS, Kirollos R. Outcome of microsurgical excision of unruptured brain arteriovenous malformations in ARUBA-eligible patients. Br J Neurosurg 2016;30:619-622.
18. Wong J, Slomovic A, Ibrahim G, Radovanovic I, Tymianski M. Microsurgery for ARUBA trial (a randomized trial of unruptured brain arteriovenous malformation)-eligible unruptured brain arteriovenous malformations. Stroke 2017;48:136-144.
20. Howard J, Trevick S, Younger DS. Epidemiology of multiple sclerosis. Neurol Clin 2016;34:919-939.
23. Hashan MR, Ghozy S, El-Qushayri AE, Pial RH, Hossain MA, Al Kibria GM. Association of dengue disease severity and blood group: a systematic review and meta-analysis. Rev Med Virol 2021;31:1-9.
27. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898
29. Lv X, Wu Z, Li Y, Yang X, Jiang C. Hemorrhage risk after partial endovascular NBCA and ONYX embolization for brain arteriovenous malformation. Neurol Res 2012;34:552-556.
30. Pulli B, Stapleton CJ, Walcott BP, Koch MJ, Raymond SB, Leslie-Mazwi TM, et al. Comparison of predictive grading systems for procedural risk in endovascular treatment of brain arteriovenous malformations: analysis of 104 consecutive patients. J Neurosurg 2019;133:342-350.
31. Pulli B, Chapman PH, Ogilvy CS, Patel AB, Stapleton CJ, Leslie-Mazwi TM, et al. Multimodal cerebral arteriovenous malformation treatment: a 12-year experience and comparison of key outcomes to ARUBA. J Neurosurg 2019;133:1792-1801.
32. Schramm J, Schaller K, Esche J, Boström A. Microsurgery for cerebral arteriovenous malformations: subgroup outcomes in a consecutive series of 288 cases. J Neurosurg 2017;126:1056-1063.
34. Abecassis IJ, Nerva JD, Feroze A, Barber J, Ghodke BV, Kim LJ, et al. Multimodality management of Spetzler-Martin grade 3 brain arteriovenous malformations with subgroup analysis. World Neurosurg 2017;102:263-274.
35. Ding D, Starke RM, Kano H, Lee JY, Mathieu D, Pierce J, et al. Stereotactic radiosurgery for Spetzler-Martin Grade III arteriovenous malformations: an international multicenter study. J Neurosurg 2017;126:859-871.
37. Chang TC, Shirato H, Aoyama H, Ushikoshi S, Kato N, Kuroda S, et al. Stereotactic irradiation for intracranial arteriovenous malformation using stereotactic radiosurgery or hypofractionated stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 2004;60:861-870.
38. Mathis JA, Barr JD, Horton JA, Jungreis CA, Lunsford LD, Kondziolka DS, et al. The efficacy of particulate embolization combined with stereotactic radiosurgery for treatment of large arteriovenous malformations of the brain. AJNR Am J Neuroradiol 1995;16:299-306.
39. Dawson RC 3rd, Tarr RW, Hecht ST, Jungreis CA, Lunsford LD, Coffey R, et al. Treatment of arteriovenous malformations of the brain with combined embolization and stereotactic radiosurgery: results after 1 and 2 years. AJNR Am J Neuroradiol 1990;11:857-864.
40. Miyachi S, Negoro M, Okamoto T, Kobayashi T, Kida Y, Tanaka T, et al. Embolisation of cerebral arteriovenous malformations to assure successful subsequent radiosurgery. J Clin Neurosci 2000;7 Suppl 1:82-85.
41. Chen JC, Mariscal L, Girvigian MR, Vanefsky MA, Glousman BN, Miller MJ, et al. Hypofractionated stereotactic radiosurgery for treatment of cerebral arteriovenous malformations: outcome analysis with use of the modified arteriovenous malformation scoring system. J Clin Neurosci 2016;29:155-161.
42. Wang HC, Chang RJ, Xiao F. Hypofractionated stereotactic radiotherapy for large arteriovenous malformations. Surg Neurol Int 2012;3(Suppl 2):S105-S110.
43. Boström JP, Bruckermann R, Pintea B, Boström A, Surber G, Hamm K. Treatment of cerebral arteriovenous malformations with radiosurgery or hypofractionated stereotactic radiotherapy in a consecutive pooled linear accelerator series. World Neurosurg 2016;94:328-338.
44. Potts MB, Zumofen DW, Raz E, Nelson PK, Riina HA. Curing arteriovenous malformations using embolization. Neurosurg Focus 2014;37:E19
47. Hernesniemi JA, Dashti R, Juvela S, Väärt K, Niemelä M, Laakso A. Natural history of brain arteriovenous malformations: a longterm follow-up study of risk of hemorrhage in 238 patients. Neurosurgery 2008;63:823-829 discussion 829-831
48. Stapf C, Mast H, Sciacca RR, Choi JH, Khaw AV, Connolly ES, et al. Predictors of hemorrhage in patients with untreated brain arteriovenous malformation. Neurology 2006;66:1350-1355.
49. D’Aliberti G, Talamonti G, Piparo M, Debernardi A, Zella S, Boccardi E, et al. Venous flow rearrangement after treatment of cerebral arteriovenous malformations: a novel approach to evaluate the risks of treatment. World Neurosurg 2014;82:160-169.
50. Derdeyn CP, Zipfel GJ, Albuquerque FC, Cooke DL, Feldmann E, Sheehan JP, et al, American Heart Association Stroke Council. Management of brain arteriovenous malformations: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2017;48:e200-e224.
51. Singfer U, Hemelsoet D, Vanlangenhove P, Martens F, Verbeke L, Van Roost D, et al. Unruptured brain arteriovenous malformations: primary ONYX embolization in ARUBA (a randomized trial of unruptured brain arteriovenous malformations)-eligible patients. Stroke 2017;48:3393-3396.